Cebix, Inc.

📍 San Diego, United States🗓 Founded 2008👥 3 employees💰 Last funded Jun 2009
Pharmaceuticals🌐 cebix.com
Website LinkedIn
Cebix is developing Ersatta™, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes. Ersatta is a long-acting form of C-peptide that, unlike other products simply directed at symptomatic relief, has the potential to reverse the chronic complications of diabetes. Cebix is evaluating Ersatta in a Phase 2 clinical trial in patients with type 1 diabetes. Type 1 and some type 2 diabetic patients have a C-peptide deficiency, which can cause a reduction in microvascular circulation, resulting in progressive damage to the nerves, retina and kidneys. This damage contributes to the onset of peripheral neuropathy, retinopathy, nephropathy and autonomic neuropathy, all chronic, long-term complications of diabetes. There are currently few treatment options for these complications of diabetes, and there are no approved drugs to treat the microvascular damage.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2008
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Cebix, Inc.?
Cebix, Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Cebix, Inc. last raise funding?
The most recent investment in Cebix, Inc. recorded on gritt.io was in June 2009.
When was Cebix, Inc. founded?
Cebix, Inc. was founded in 2008.
What industry is Cebix, Inc. in?
Cebix, Inc. operates in Pharmaceuticals. Find similar Pharmaceuticals investors on gritt.io.
Where is Cebix, Inc. based?
Cebix, Inc. is headquartered in San Diego, United States.